CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.925
EU - Europa 7.203
AS - Asia 6.660
SA - Sud America 1.068
AF - Africa 266
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 10
AN - Antartide 1
Totale 23.166
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.702
RU - Federazione Russa 3.427
SG - Singapore 2.471
CN - Cina 1.848
IT - Italia 846
BR - Brasile 798
GB - Regno Unito 798
VN - Vietnam 710
HK - Hong Kong 584
FR - Francia 438
DE - Germania 429
IE - Irlanda 362
BD - Bangladesh 341
SE - Svezia 271
FI - Finlandia 191
KR - Corea 191
UA - Ucraina 134
IN - India 121
AR - Argentina 103
CA - Canada 103
NL - Olanda 65
NG - Nigeria 62
ID - Indonesia 60
MX - Messico 57
EC - Ecuador 55
JP - Giappone 47
BJ - Benin 44
TR - Turchia 43
ZA - Sudafrica 43
AT - Austria 42
CO - Colombia 41
IQ - Iraq 41
PL - Polonia 41
ES - Italia 33
AU - Australia 31
PK - Pakistan 29
SA - Arabia Saudita 24
TN - Tunisia 24
CL - Cile 20
BE - Belgio 19
MA - Marocco 18
UZ - Uzbekistan 17
VE - Venezuela 16
GR - Grecia 15
LT - Lituania 15
MY - Malesia 15
PH - Filippine 15
PT - Portogallo 15
TG - Togo 15
KE - Kenya 14
EG - Egitto 13
PY - Paraguay 13
CH - Svizzera 11
PE - Perù 11
AE - Emirati Arabi Uniti 10
TH - Thailandia 10
CR - Costa Rica 9
IL - Israele 9
JM - Giamaica 9
NI - Nicaragua 9
NP - Nepal 9
DO - Repubblica Dominicana 7
EU - Europa 7
OM - Oman 7
AL - Albania 6
BO - Bolivia 6
HN - Honduras 6
KG - Kirghizistan 6
KZ - Kazakistan 6
RO - Romania 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
DK - Danimarca 5
ET - Etiopia 5
IR - Iran 5
JO - Giordania 5
PS - Palestinian Territory 5
QA - Qatar 5
AO - Angola 4
AZ - Azerbaigian 4
BG - Bulgaria 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
HU - Ungheria 4
RS - Serbia 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
CI - Costa d'Avorio 3
HR - Croazia 3
KH - Cambogia 3
LB - Libano 3
PA - Panama 3
PR - Porto Rico 3
UY - Uruguay 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BY - Bielorussia 2
GT - Guatemala 2
LV - Lettonia 2
Totale 23.125
Salva come PNG Salva come JPEG
Città #
Singapore 1.292
Moscow 1.129
Ashburn 1.098
San Jose 1.043
Dallas 917
Southend 592
Hong Kong 578
Chandler 569
Jacksonville 562
Dublin 354
Beijing 353
Verona 316
The Dalles 310
Ho Chi Minh City 229
New York 208
Council Bluffs 174
Munich 166
Hanoi 161
Los Angeles 161
Lawrence 152
Princeton 152
Wilmington 150
Jinan 130
Woodbridge 113
Nanjing 111
Shenyang 110
Helsinki 109
Buffalo 90
Houston 88
São Paulo 84
Redondo Beach 83
Tianjin 76
Hebei 68
London 56
Santa Clara 55
Milan 51
Abuja 48
Zhengzhou 47
Orem 45
Cotonou 44
Sindelfingen 44
Tokyo 41
Changsha 40
Taizhou 40
Frankfurt am Main 39
Guangzhou 37
Jiaxing 37
Columbus 36
Haikou 36
Ann Arbor 35
Bologna 35
Dearborn 35
Redmond 35
Jakarta 34
Grafing 33
Toronto 33
Warsaw 33
Hangzhou 32
Dong Ket 31
Montreal 31
Ningbo 31
Haiphong 30
Rome 30
Brooklyn 29
Chicago 29
Nanchang 29
Seattle 29
Taiyuan 27
Chennai 26
Turku 26
Guayaquil 25
Rio de Janeiro 25
San Francisco 25
Lanzhou 24
Norwalk 24
Johannesburg 23
Denver 22
Belo Horizonte 21
Boston 21
Nuremberg 21
Amsterdam 20
Mexico City 20
Redwood City 20
Vienna 20
Baghdad 19
Dhaka 19
Fuzhou 19
Stockholm 19
Atlanta 18
Washington 18
Da Nang 17
Mumbai 17
Phoenix 17
Salvador 17
Biên Hòa 16
Boardman 16
Lappeenranta 16
Manchester 16
Melbourne 16
Seoul 16
Totale 13.664
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 238
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 232
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 220
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 217
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 202
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 201
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 201
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 191
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 190
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 181
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 181
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 178
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 177
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 176
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 173
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 172
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 170
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 169
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 169
A prognostic model for patients with lymphoma and {COVID}-19: a multicentre cohort study 168
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 165
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 165
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 164
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 160
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 160
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 160
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 160
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 160
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 158
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis 156
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 155
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis 153
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 152
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 152
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 151
Autoimmune cytopenias in chronic lymphocytic leukemia 151
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 151
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report 149
Genetic and phenotypic attributes of splenic marginal zone lymphoma 149
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 147
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 147
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 146
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 145
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 145
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 143
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 141
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 140
Bendamustine plus rituximab: is it a BRIGHT idea? 140
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 140
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 138
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 138
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 138
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 137
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 134
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 134
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 134
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 134
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 133
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 133
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and {CAR}-T Cell Therapy 129
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 128
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 128
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 128
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 127
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma 123
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 123
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 122
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 122
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 121
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 121
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma 120
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 120
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 119
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 119
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 119
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 118
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 116
Aggressive B-cell Lymphoma with {MYC}/{TP}53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents 116
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 115
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 115
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 113
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 113
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 112
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 112
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 112
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 112
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 111
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 110
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 109
Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium 109
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 108
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 108
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 108
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 108
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 108
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 107
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study 105
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 104
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 104
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 102
Totale 14.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.718
article - articoli 76.787
book - libri 0
conference - conferenze 5.931
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 0 0 0 0 0 0 0 0 53
2021/2022915 52 197 17 44 35 27 46 64 35 29 58 311
2022/20231.992 168 170 210 271 186 523 31 114 214 18 49 38
2023/20241.080 38 93 82 103 99 215 50 106 12 33 174 75
2024/20253.537 204 188 87 571 132 141 176 213 506 271 313 735
2025/202613.155 738 885 811 1.713 3.351 803 1.057 750 1.252 716 515 564
Totale 23.443